
OncoInv Aims to Expand Access to Early Multi-Cancer Detection Worldwide
3 min read
OncoInv is working to make multi-cancer detection more accessible, particularly in underserved healthcare markets. Through OncoSeek®, a clinically validated blood test that assesses the probability of nine cancer types, the company aims to support earlier detection and address inequalities in access to cancer screening.

Cancer is often detected at an advanced stage, particularly in countries where access to screening and diagnostic services remains limited. OncoInv is working to address this challenge through a model that combines multi-cancer detection technology with international partnerships to expand access to earlier testing.
Jesper Verhey, CEO of OncoInv, presented the company's approach to accessible multi-cancer detection at the Health~Holland Global Investor Forum 2026. Watch his pitch presentation to learn more about OncoInv's mission and how it aims to bring cancer detection to underserved markets worldwide.
Expanding access to multi-cancer detection
OncoInv focuses on improving access to cancer detection in markets where conventional single-cancer screening programmes may be difficult to implement or access.
At the centre of its approach is OncoSeek®, a blood-based test developed by SeekIn that analyses concentrations of protein tumour markers using a machine learning algorithm. The test assesses the probability of nine high-impact cancer types and provides both a Probability of Cancer score and a predicted Tissue of Origin.
Rather than focusing on one specific cancer, this multi-cancer approach aims to provide information across several cancer types through a single test. OncoSeek® is CE-marked and supported by peer-reviewed scientific publications, providing an evidence base for its implementation in different healthcare settings.
A scalable model built around local partnerships
Making cancer detection more accessible requires more than developing a test. It also involves establishing the infrastructure, distribution channels and clinical pathways needed to bring testing to the people who need it.
OncoInv operates through an asset-light model, collaborating with authorised distributors and clinical partners rather than building and operating its own laboratory infrastructure. This allows the company to work with existing healthcare systems and local organisations, adapting implementation to the needs and resources of individual markets.
Testing can be performed through laboratories in Europe or, where appropriate, through local laboratory partners. An essential part of this model is ensuring that individuals with positive results receive appropriate follow-up from healthcare professionals, including clear guidance on the next steps.
The company also applies a differential pricing model based on World Bank income classifications. Its activities in low- and middle-income countries are organised on a not-for-profit basis, with the aim of reducing financial barriers and supporting more equitable access to multi-cancer detection.
Supporting earlier detection in underserved markets
OncoInv's approach is particularly relevant in low- and middle-income countries, where cancer is frequently diagnosed at a later stage and access to treatment can be limited.
Beyond screening programmes and routine health checks, OncoSeek® may also be used for individuals with an elevated cancer risk profile, people presenting with symptoms, or as a triage tool to support the prioritisation of diagnostic waiting lists.
The company has already established an initial international presence across different countries and income settings, with further expansion underway in Southeast Asia and the Middle East.
Through its collaboration with SeekIn and local healthcare partners, OncoInv aims to bring multi-cancer detection closer to the communities that currently face the greatest barriers to accessing it.
Pitch at Global Investor Forum
OncoInv presented its approach to accessible multi-cancer detection at Health~Holland Global Investor Forum 2026, connecting innovative life sciences and healthcare companies with investors and industry stakeholders.
The next edition of the Health~Holland Global Investor Forum takes place on 10 March 2027 in Utrecht, the Netherlands, alongside Innovation for Health on 11 March.
Are you developing an innovative biotech, medtech, healthcare or life sciences company and looking to connect with investors and industry partners? The Global Investor Forum offers selected start-ups and scale-ups the opportunity to present their innovations to an international audience.
Interested in pitching your company? Book your pitching slot via the Global Investor Forum website.




